Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
about
Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial.Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines.BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.
P2860
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Total genomic alteration as me ...... ents treated with azacitidine.
@en
Total genomic alteration as me ...... ents treated with azacitidine.
@nl
type
label
Total genomic alteration as me ...... ents treated with azacitidine.
@en
Total genomic alteration as me ...... ents treated with azacitidine.
@nl
prefLabel
Total genomic alteration as me ...... ents treated with azacitidine.
@en
Total genomic alteration as me ...... ents treated with azacitidine.
@nl
P2093
P2860
P356
P1433
P1476
Total genomic alteration as me ...... ients treated with azacitidine
@en
P2093
C Moreilhon
J G Fuzibet
J Gutnecht
J-M Karsenti
J-P Cassuto
N Montagne
P2860
P2888
P356
10.1038/BCJ.2013.52
P577
2013-11-01T00:00:00Z